Forte Biosciences Files Definitive Proxy Statement
Ticker: FBRX · Form: DEF 14A · Filed: Jul 30, 2024 · CIK: 1419041
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: FBRX
TL;DR
Forte Bio (FBRX) proxy filed. Annual meeting Aug 20. Vote your shares!
AI Summary
Forte Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on July 30, 2024, for its annual meeting on August 20, 2024. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. The company, formerly known as Tocagen Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals or director elections, allowing them to make informed voting decisions.
Risk Assessment
Risk Level: low — A DEF 14A filing is a routine disclosure and does not inherently represent new financial risk.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Tocagen Inc. (company) — Former company name
- 20240820 (date) — Annual meeting date
- 20240730 (date) — Filing date
- 001-38052 (other) — SEC file number
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to solicit proxies from shareholders for the annual meeting of Forte Biosciences, Inc.
When is the annual meeting of Forte Biosciences, Inc. scheduled?
The annual meeting of Forte Biosciences, Inc. is scheduled for August 20, 2024.
What was Forte Biosciences, Inc. formerly known as?
Forte Biosciences, Inc. was formerly known as Tocagen Inc.
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on July 30, 2024.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,849 words · 19 min read · ~16 pages · Grade level 10.7 · Accepted 2024-07-30 16:05:52
Filing Documents
- d868251ddef14a.htm (DEF 14A) — 644KB
- g868251g00a01.jpg (GRAPHIC) — 154KB
- g868251g00a02.jpg (GRAPHIC) — 133KB
- g868251g19n78.jpg (GRAPHIC) — 18KB
- g868251g26k02.jpg (GRAPHIC) — 30KB
- g868251g51a83.jpg (GRAPHIC) — 112KB
- g868251g51a84.jpg (GRAPHIC) — 116KB
- 0001193125-24-188850.txt ( ) — 1405KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 45 Processes and Procedures for Compensation Decisions 45 Employment Arrangements 46 Outstanding Equity Awards at Fiscal 2023 Year-End 48 Table of Contents Page
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ANDMANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ANDMANAGEMENT 54 RELATED PERSON TRANSACTIONS 58 Policies and Procedures for Related Person Transactions 59 OTHER MATTERS 60 2023 Annual Report 60 ii Table of Contents FORTE BIOSCIENCES, INC. PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To be held at 8:00 a.m., Central Time, on Tuesday, August 20, 2024 The information provided in the question and answer format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully. QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR ANNUAL MEETING Why am I receiving these materials? This proxy statement and the form of proxy are furnished in connection with the solicitation of proxies by our Board of Directors (the Board) for use at the 2024 Annual Meeting of stockholders of Forte Biosciences, Inc. (the Company or Forte), a Delaware corporation, and any postponements, adjournments or continuations thereof. The Annual Meeting will be held on Tuesday, August 20, 2024, at 8:00 a.m., Central Time. The Annual Meeting will be conducted virtually via live audio webcast. You will be able to attend the Annual Meeting virtually by visiting www.virtualshareholdermeeting.com/FBRX2024, where you will be able to listen to the meeting live and vote online during the meeting. What proposals will be voted on at the Annual Meeting? The following proposals will be voted on at the Annual Meeting: the election of Barbara K. Finck, M.D., Donald A. Williams, and Stephen K. Doberstein, Ph.D. as the three (3) Class I directors to hold office until our 2027 annual meeting of stockholders and until his or her respective successors are elected and qualified; the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for our the approval of an amended and restated